FY23 interim results showed a sharp short-term decline in revenue. With a recovery expected in H2, our expectations are being maintained for a 12% y-o-y increase in revenue for FY2023. Loss at the EBITDA level was £1m (FY22 H1: loss of £250k), reflecting higher CoGS and R&D spend. Fusion’s results come ahead of a key milestone in the form of the move into commercialisation of OptiMAL, which has the potential to become an important revenue source in the future. We expect further growth in revenue ....
05 Dec 2022
Fusion Antibodies Interims
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Fusion Antibodies Interims
Fusion Antibodies Plc (FAB:LON) | 3.8 0 0.0% | Mkt Cap: 3.58m
- Published:
05 Dec 2022 -
Author:
Robin Davison -
Pages:
5
FY23 interim results showed a sharp short-term decline in revenue. With a recovery expected in H2, our expectations are being maintained for a 12% y-o-y increase in revenue for FY2023. Loss at the EBITDA level was £1m (FY22 H1: loss of £250k), reflecting higher CoGS and R&D spend. Fusion’s results come ahead of a key milestone in the form of the move into commercialisation of OptiMAL, which has the potential to become an important revenue source in the future. We expect further growth in revenue ....